公开(公告)号：US20140243420A1

公开(公告)日：2014-08-28

申请号：US14130702

申请日：2012-07-04

Applicant: Peter De Witte ,  Camila V. Esguerra ,  Alexander D. Crawford ,  Adriana Monserrath Orellana Paucar

Inventor： Peter De Witte ,  Camila V. Esguerra ,  Alexander D. Crawford ,  Adriana Monserrath Orellana Paucar

IPC: A61K31/12

CPC classification number: A61K31/12 ,  A61K31/121 ,  A61K36/9066

Abstract: The present invention relates to the anti-convulsant activity of turmeric oil and its volatile bisabolene sesquiterpenoids ar-turmerone, α-turmerone, β-turmerone (curlone) and α-atlantone, as an anticonvulsant agent for the treatment of epilepsy and/or as therapeutic agents for the treatment of disorders of the central nervous system, including tremor, pain, mood disorders (including depression, bipolar disorder, attention deficit-hyperactivity disorder, and schizophrenia), and neurodegenerative diseases.

Abstract translation: 本发明涉及姜黄油及其挥发性双酯倍半萜类阿魏酮，α-姜黄酮，β-榄香烯（卷曲酮）和α-阿特兰通的抗惊厥活性，作为治疗癫痫的抗惊厥剂和/或 作为治疗中枢神经系统疾病的治疗剂，包括震颤，疼痛，情绪障碍（包括抑郁症，双相情感障碍，注意力缺陷 - 多动症和精神分裂症）和神经变性疾病。

公开(公告)号：US20110038795A1

公开(公告)日：2011-02-17

申请号：US12744798

申请日：2008-11-26

Applicant: Yicheng Ni ,  Marie Van De Putte ,  Peter De Witte ,  Alfons Verbruggen ,  Guy Marchal ,  Ziping Sun

Inventor： Yicheng Ni ,  Marie Van De Putte ,  Peter De Witte ,  Alfons Verbruggen ,  Guy Marchal ,  Ziping Sun

IPC: A61K51/04 ,  A61P35/00

CPC classification number: A61K51/04

Abstract: The present invention concerns a therapeutically labeled napthodianthrone or phenanthro[1,10,9,8-opqra]perylene-7,14-dione compound, which comprises a chemical element or an isotope that has an unstable nucleus and emits radiation during its decay to a stable form sufficient to destroy neighboring cells or tissues for use in a targeted radiotherapy to enhance curability of a warm-blooded animal that has been subjected to a necrosis-inducing antitumor therapy. A particular advantage of present invention is that viable rim resistant to a necrosis-inducing antitumor therapy such as vascular targeting agent (VTA) can be supplemented by one single or repeated doses of a therapeutically radiolabeled small molecule necrosis-avid chemical compound treatment to enhance the curability. Examples of necrosis inducing therapies are for instance minimally invasive tumor ablations applied chemically by percutaneous injection of ethanol or acetic acid, or physically by cryotherapy, microwave, focused ultrasound, interstitial laser therapy and radio-frequency ablation (RFA); by chemotherapies using cytotoxic agents or vascular targeting agents (VTA); and by external or internal radiotherapies.

Abstract translation: 本发明涉及一种治疗上标记的阴蒂龙酮或菲咯啉[1,10,9,8-吖庚因]二萘嵌苯-7,14-二酮化合物，其包含具有不稳定核的化学元素或同位素，并在其衰变期间发射辐射 足以破坏用于靶向放射治疗的相邻细胞或组织的稳定形式，以增强已经进行坏死诱导的抗肿瘤治疗的温血动物的固化性。 本发明的一个特别优点是可以通过一种单独或重复剂量的治疗性放射性标记的小分子坏死的化学化合物治疗来补充对坏死诱导的抗肿瘤治疗如血管靶向剂（VTA）有抗性的活性边缘，以增强 固化性 坏死诱导疗法的实例是例如通过经皮注射乙醇或乙酸而化学施用的微创肿瘤消融，或通过冷冻治疗，微波，聚焦超声，间质激光治疗和射频消融（RFA）物理化学进行的微创肿瘤消融。 通过使用细胞毒剂或血管靶向剂（VTA）的化疗; 以及外部或内部放射治疗。